ESMO: European Society for Medical Oncology

  1. Description of the incidence and risk of co-morbidities developing subsequent to cancer treatment aids in creating tailored survivorship care

  2. New indication concerns maintenance treatment of adults with advanced ovarian cancer who are in response following completion of first-line platinum-based chemotherapy

  3. New indication concerns a combination with bevacizumab for the treatment of adults with advanced or unresectable hepatocellular carcinoma who have not received prior systemic therapy

  4. New indication concerns their combination with 2 cycles of platinum-based chemotherapy in first-line treatment of metastatic NSCLC without sensitising EGFRmutation or ALKtranslocation

  5. New indications concern the maintenance treatment in combination with bevacizumab of ovarian cancer with HRD positive status and monotherapy of mCRPC with BRCA1/2 mutations